Amgen has today agreed to buy Dublin headquartered Horizon Therapeutics in a deal valued at 27.8. Reference: AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC. French health group Sanofi said yesterday that it no longer intends to make an offer for Horizon. "We have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a broader range of diseases." In recent trading, shares of Horizon Therapeutics plc (Symbol: HZNP) have crossed above the average analyst 12-month target price of 111.20, changing hands for 112.36/share. "Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world suffering from serious illnesses," said Robert A. Acceleration of revenue growth expected to be accretive to non-GAAP earnings per share from 2024. The Federal Trade Commission said it would pause its in-house proceedings to block Amgen Inc.’s 27.8 billion takeover of Horizon Therapeutics Plc, opening the door to settlement talks that.Generating robust cash flow to support capital allocation priorities, including ongoing investment in innovation while sustaining a commitment to an investment grade credit rating.Intrinsic Value: Projected FCF explanation. Leveraging of Amgen's world-class capabilities in biologics research and development, process development and manufacturing, as well as Amgen's presence in more than 100 countries around the world. Horizon Therapeutics (FRA:HPR) Intrinsic Value: Projected FCF as of today (October 18, 2023) is 50.22.Strengthening of Amgen's leading inflammation portfolio by adding first-in-class, early-in-lifecycle medicines such as Tepezza (teprotumumab-trbw), Krystexxa (pegloticase) and Uplizna (inebilizumab-cdon), which treat rare inflammatory diseases. (Reuters) - Amgen said on Friday it had completed the 27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S.Compared to the current market price of 116.3 USD, the stock is Overvalued by 27. Estimated DCF Value of one HZNP stock is 85.21 USD. Whats The Estimated Valuation Were using the 2-stage growth model, which simply means we take in account two stages of companys growth. Alignment with Amgen's core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases. This DCF valuation model was created by Alpha Spread and was last updated on Dec 1, 2023.While Horizon Therapeutics Public Limited Company' s Revenue increase of 7.71% ranks overall at the positon no. Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 124 other companies have achieved higher Revenue growth. Horizon Therapeutics Public Limited Company reported Revenue growth of 7.71% year on year in the second quarter 2023, to $ 944.00 millions, this is lower than Horizon Therapeutics Public Limited Company's recent average Revenue rise of 97.47%. HZNP Revenue second quarter 2023 Y/Y Growth Comment Income from Continued Operations Annual Growth.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |